文献速递心力衰竭与心肌病

ADVOR 试验:肾功能与乙酰唑胺在急性失代偿性心衰中的减容效应

Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial.
PubMed 文献 · Eur Heart J · 2023-01-01

ADVOR 试验的预先设定分析纳入 519 例急性失代偿性心衰患者,在静脉袢利尿剂基础上随机加用静脉乙酰唑胺或安慰剂。结果显示乙酰唑胺在全 eGFR 范围内一致提高减容成功率,低 eGFR 患者利尿利钠效应更显著;治疗期肾功能恶化更常见但 3 个月肌酐无差异,且未增加心衰住院和死亡。

要点

  • 治疗期肾功能恶化更常见(40.5% vs 18.9%),但 3 个月肌酐无差异。

核心结论

  • 乙酰唑胺在全肾功能范围内与更高的减容成功率相关,低 eGFR 患者利尿利钠效应更明显。
  • 乙酰唑胺治疗期肾功能恶化更常见,但未与心衰住院和死亡增加相关。

研究设计与样本

  • ADVOR 试验的预先设定分析,随机 519 例急性失代偿性心衰患者。
  • 在静脉袢利尿剂基础上加用静脉乙酰唑胺或匹配安慰剂。

主要发现

  • 入院时中位 eGFR 为 40(30-52)mL/min/1.73 m²。

关键数值与推荐

  • 治疗期肾功能恶化定义:肌酐升高≥0.3 mg/dL。

临床怎么用

  • 急性失代偿性心衰患者在静脉袢利尿剂基础上可考虑加用静脉乙酰唑胺以促进减容。
  • 低 eGFR 患者使用乙酰唑胺时利钠利尿效应可能更明显。
  • 治疗期出现肾功能恶化不一定预示不良临床结局,出院时减容与较低不良结局相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: In the ADVOR trial, acetazolamide improved decongestion in acute decompensated heart failure (ADHF). Whether the beneficial effects of acetazolamide are consistent across the entire range of renal function remains unclear. METHODS: This is a pre-specified analysis of the ADVOR trial that randomized 519 patients with ADHF to intravenous acetazolamide or matching placebo on top of intravenous loop diuretics. The main endpoints of decongestion, diuresis, natriuresis, and clinical outcomes are assessed according to baseline renal function. Changes in renal function are evaluated between treatment arms. RESULTS: On admission, median estimated glomerular filtration rate (eGFR) was 40 (30-52) mL/min/1.73 m². Acetazolamide consistently increased the likelihood of decongestion across the entire spectrum of eGFR (P-interaction = .977). Overall, natriuresis and diuresis were higher with acetazolamide, with a higher treatment effect for patients with low eGFR (both P-interaction < .007). Acetazolamide was associated with a higher incidence of worsening renal function (WRF; rise in creatinine ≥ 0.3 mg/dL) during the treatment period (40.5% vs. 18.9%; P < .001), but there was no difference in creatinine after 3 months (P = .565). This was not associated with a higher incidence of heart failure hospitalizations and mortality (P-interaction = .467). However, decongestion at discharge was associated with a lower incidence of adverse clinical outcomes irrespective of the onset of WRF (P-interaction = .805). CONCLUSIONS: Acetazolamide is associated with a higher rate of successful decongestion across the entire range of renal function with more pronounced effects regarding natriuresis and diuresis in patients with a lower eGFR. While WRF occurred more frequently with acetazolamide, this was not associated with adverse clinical outcomes. CLINICALTRIALS.GOV IDENTIFIER: NCT03505788.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Meekers, Dauw, Martens, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023. PMID: 37623428. doi:10.1093/eurheartj/ehad557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。